Type 2 Diabetes Clinical Trial
Official title:
Safety/Efficacy Assessed Study on Transplantation Therapy Using Human Umbilical Cord/Placenta-derived Mesenchymal Stem Cells for Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) derived from human umbilical cord/placenta at a dose of 1.0E+6 MSC/kg for type 2 diabetes.
1. Intervention Details: Biological: umbilical cord/placenta-derived mesenchymal stem cells;
Drug: 1. Oral Hypoglycemic Drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al.
2. Insulins.
1. 1st transplantation: after finishing all required examines according to protocol in Day
0, umbilical cord/placenta-derived MSCs are transplanted intravenously.
2. 2nd transplantation: after finishing all required examines in Day 90, umbilical
cord/placenta-derived-MSCs are transplanted intravenously if the effects of MSC are
better than that before.
3. At the same time, patients continue taking the oral hypoglycemic drugs, insulins or the
combination of the oral hypoglycemic drugs and insulins which the patients have taken
for controlling the higher blood sugar from Day 0 for 1 year. But the dose of the oral
hypoglycemic drugs and insulins should be regulated according to the level of blood
sugar.
2. Detailed Description:
1. To evaluate the feasibility and safety of transplantation treatment using umbilical
cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus
undergoing the oral hypoglycemic drugs, insulins or the combination of the oral
hypoglycemic drugs and insulins.
2. To assess efficacy of transplantation treatment using umbilical cord/placenta-derived
mesenchymal stem cells in patients with type 2 diabetes mellitus undergoing the oral
hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and
insulins.
3. This study will last 2 to 3 years. Participants will be randomly assigned to receive
either MSC transplant and the oral hypoglycemic drugs or MSC transplant and insulins or
MSC transplant and the combination of the oral hypoglycemic drugs and insulins
(experimental group) or the oral hypoglycemic drugs or insulins or the combination of
the oral hypoglycemic drugs and insulins (control group). Patients will undergo MSC
transplant at the start of the study on Day 0 and take the oral hypoglycemic drugs,
insulins or the combination of the oral hypoglycemic drugs and insulins for 1 year. As
control, some patients take the oral hypoglycemic drugs, insulins or the combination of
the oral hypoglycemic drugs and insulins for 1 year. At the same time, the dose of the
oral hypoglycemic drugs and insulins should be regulated according to the level of
blood sugar. After 3 months, patients will receive the second MSC transplantation.
After six and twelve months from the first transplantation, patients will be evaluated.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |